



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd Off: 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh – 452 011. Phone : +91 9884624100

Date: 06th May 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers
21st Floor, Dalal Street
Mumbai – 400001

BSE Scrip Code: 524322

Sub: Press Release

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”)

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, (“Listing Regulation”), we hereby enclose a copy of the Press Release titled “Kabra Drugs Limited Announces Strategic Expansion of Pharmaceutical Manufacturing, AI-Driven Defense Technologies & Leadership Appointment”.

The above can also be accessed on the website of the Company at www.kabradrugs.com

Kindly take the aforesaid information on record and oblige.

Thanking you,

Yours sincerely,

For Kabra Drugs Limited

Kuniamuthur Nanjappan Anand

Director

DIN: 03230186



Kabra Drugs Limited Announces Strategic Expansion of Pharmaceutical Manufacturing, AI-Driven Defense Technologies & Leadership Appointment

Chennai, India: May 06, 2026

Kabra Drugs Limited has announced key strategic initiatives approved by its Board of Directors aimed at accelerating growth across pharmaceutical manufacturing, AI-integrated defense technologies, and advanced research & development.

Strategic Growth Initiatives

1. Pharmaceutical Manufacturing & Marketing Expansion

- Board approved expansion of pharmaceutical manufacturing and marketing of the Company's own generic branded formulations.
- The expansion shall be executed in phases through strategic channel partners arranged by the company "Mr. Franchise", an external Agency.
- Phase 1 to focus on strengthening presence across South India, with subsequent phases to follow for expansion.
- Managing Director Mr. N. Aravind has been authorized to execute agreements with channel partners, subject to completion of due diligence procedures, and has initiate the project implementation immediately.

This initiative is expected to strengthen the Company's presence in high-growth therapeutic markets and improve access to affordable healthcare solutions.

2. Defence & AI Integration

- Board evaluated opportunities in defence manufacturing leveraging Artificial Intelligence (AI).
- Company to initiate regulatory approval process with DGFT for obtaining SCOMET License.
- Dedicated AI & defence Technology R&D facility to be established at Cactus TECCI Park, Chennai.

This facility will serve as a hub for innovation in AI-driven defence technologies, positioning the Company as a contributor to national security and advanced manufacturing capabilities.

3. Strategic Appointment

- Mr. Alagiamaavalan appointed as Independent Consultant for domestic and international defence projects.

Speaking on the strategic growth initiatives, Mr. N. Aravind, Managing Director, said: “These strategic initiatives reflect the Company’s commitment toward diversification, innovation, and long-term value creation. Our expansion into pharmaceuticals and AI-led defense technologies positions us to capitalize on emerging opportunities across high-growth sectors while strengthening our operational capabilities and future readiness.”

About Kabra Drugs Limited

Kabra Drugs Limited (Kabra Drugs) is a research-driven pharmaceutical company focused on specialty formulations, injectables, and APIs. Founded with the vision of making quality healthcare science-driven and accessible, the Company is committed to delivering safe, effective, and globally competitive pharmaceutical solutions. Backed by WHO-GMP aligned systems, advanced manufacturing capabilities, and innovation-led processes, Kabra Drugs continues to strengthen its presence across key therapeutic areas while maintaining a strong focus on quality, integrity, and responsible growth.

Note: The following short forms have been used in this document — AI (Artificial Intelligence), DGFT (Directorate General of Foreign Trade), SCOMET (Special Chemicals, Organisms, Materials, Equipment and Technologies), R&D (Research and Development), APIs (Active Pharmaceutical Ingredients), WHO-GMP (World Health Organization - Good Manufacturing Practices).

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor



AKMIL Strategic Advisors Private Limited
Mr. Milind Apte – Director
milind@akmiladvisors.com
+91 98209 41925
www.akmiladvisors.com